320 related articles for article (PubMed ID: 12580648)
1. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients.
Cestac P; Bagheri H; Lapeyre-Mestre M; Sié P; Fouladi A; Maupas E; Léger P; Fontan B; Massip P; Montastruc JL
Drug Saf; 2003; 26(3):197-207. PubMed ID: 12580648
[TBL] [Abstract][Full Text] [Related]
2. Modifications of low-molecular weight heparin use in a French university hospital after implementation of new guidelines.
Leclerc-Foucras S; Bagheri H; Samii K; Montastruc JL; Lapeyre-Mestre M;
Drug Saf; 2007; 30(5):409-17. PubMed ID: 17472419
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of different low-molecular weight heparins used at therapeutic dose.
Gouin-Thibault I; Pautas E; Siguret V
Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Lim W; Dentali F; Eikelboom JW; Crowther MA
Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
[TBL] [Abstract][Full Text] [Related]
6. Hemorrhagic complications in patients treated with anticoagulant doses of a low molecular weight heparin (enoxaparin) in routine hospital practice.
Ellis MH; Hadari R; Tchuvrero N; Shapira S; Kovlenko I; Kozmiakova M; Zissin R; Elis A
Clin Appl Thromb Hemost; 2006 Apr; 12(2):199-204. PubMed ID: 16708122
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol.
Jaffer AK; Ahmed M; Brotman DJ; Bragg L; Seshadri N; Qadeer MA; Klein A
J Thromb Thrombolysis; 2005 Aug; 20(1):11-6. PubMed ID: 16133889
[TBL] [Abstract][Full Text] [Related]
8. [Inappropriate prescription of heparin at curative doses in the hospital. Can the information to prescribing physicians decrease misuse?].
Geffroy CE; Couffin E; Doucet J; Carvalho P; Sibert L; Bentot C; Mouton-Schleifer D; Lévesque H; Chassagne P; Bercoff E
Presse Med; 2002 Feb; 31(7):303-11. PubMed ID: 11899684
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
10. Structured benefit-risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer.
Kürzinger ML; El-Haddad C; Gouin-Soboleva T; Fazekas Z; Granados D; Benito-Garcia E; Djoudi Y
Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5795. PubMed ID: 38680090
[TBL] [Abstract][Full Text] [Related]
11. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease.
Farooq V; Hegarty J; Chandrasekar T; Lamerton EH; Mitra S; Houghton JB; Kalra PA; Waldek S; O'Donoghue DJ; Wood GN
Am J Kidney Dis; 2004 Mar; 43(3):531-7. PubMed ID: 14981611
[TBL] [Abstract][Full Text] [Related]
12. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
[TBL] [Abstract][Full Text] [Related]
13. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
14. [Prospective randomized study comparing the effectiveness and tolerance of various low-molecular-weight heparins in high risk patients].
Janni W; Bergauer F; Rjosk D; Lohscheidt K; Hagena FW
Zentralbl Chir; 2001 Jan; 126(1):32-8. PubMed ID: 11227291
[TBL] [Abstract][Full Text] [Related]
15. Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
van Rein N; Biedermann JS; van der Meer FJM; Cannegieter SC; Wiersma N; Vermaas HW; Reitsma PH; Kruip MJHA; Lijfering WM
J Thromb Haemost; 2017 Jul; 15(7):1386-1391. PubMed ID: 28440008
[TBL] [Abstract][Full Text] [Related]
16. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study.
Mahé I; Aghassarian M; Drouet L; Bal Dit-Sollier C; Lacut K; Heilmann JJ; Mottier D; Bergmann JF
Thromb Haemost; 2007 Apr; 97(4):581-6. PubMed ID: 17393021
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
[TBL] [Abstract][Full Text] [Related]
18. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
19. Low molecular weight heparin and bleeding in patients with chronic renal failure.
Crowther M; Lim W
Curr Opin Pulm Med; 2007 Sep; 13(5):409-13. PubMed ID: 17940486
[TBL] [Abstract][Full Text] [Related]
20. Head-to-head comparison of two different low-molecular-weight heparins in acute coronary syndrome: a single center experience.
Ozdemir M; Erdem G; Türkoglu S; Cemri M; Timurkaynak T; Boyaci B; Ridvan Y; Cengel A; Dörtlemez O; Dörtlemez H
Jpn Heart J; 2002 Sep; 43(5):433-42. PubMed ID: 12452301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
